• Journal of Physiology & Pathology in Korean Medicine
• /
• v.17 no.3
• /
• pp.605-610
• /
• 2003

According to the Leukemia and Lymphoma Society, leukemia is a malignant disease (cancer) that originates in a cell in the marrow. It is characterized by the uncontrolled growth of developing marrow cells. There are two major classifications of leukemia: myelogenous or lymphocytic, which can each be acute or chronic. The terms myelogenous or lymphocytic denote the cell type involved. Thus, four major types of leukemia are: acute or chronic myelogenous leukemia and acute or chronic lymphocytic leukemia. Leukemia, lymphoma and myeloma are considered to be related cancers because they involve the uncontrolled growth of cells with similar functions and origins. The diseases result from an acquired (not inherited) genetic injury to the DNA of a single cell, which becomes abnormal (malignant) and multiplies continuously. In the United States, about 2,000 children and 27,000 adults are diagnosed each year with leukemia. Treatment for cancer may include one or more of the following: chemotherapy, radiation therapy, biological therapy, surgery and bone marrow transplantation. The most effective treatment for leukemia is chemotherapy, which may involve one or a combination of anticancer drugs that destroy cancer cells. Specific types of leukemia are sometimes treated with radiation therapy or biological therapy. Common side effects of most chemotherapy drugs include hair loss, nausea and vomiting, decreased blood counts and infections. Each type of leukemia is sensitive to different combinations of chemotherapy. Medications and length of treatment vary from person to person. Treatment time is usually from one to two years. During this time, your care is managed on an outpatient basis at M. D. Anderson Cancer Center or through your local doctor. Once your protocol is determined, you will receive more specific information about the drug(s) that Will be used to treat your leukemia. There are many factors that will determine the course of treatment, including age, general health, the specific type of leukemia, and also whether there has been previous treatment. there is considerable interest among basic and clinical researchers in novel drugs with activity against leukemia. the vast history of experience of traditional oriental medicine with medicinal plants may facilitate the identification of novel anti leukemic compounds. In the present investigation, we studied 31 kinds of anti leukemic medicinal plants, which its pharmacological action was already reported through many experimental articles and oriental medical book: 『pharmacological action and application of anticancer traditional chinese medicine』 In summary: Used leukemia cellline are HL60, HL-60, Jurkat, Molt-4 of human, and P388, L-1210, L615, L-210, EL-4 of mouse. 31 kinds of anti leukemic medicinal plants are Panax ginseng C.A Mey; Polygonum cuspidatum Sieb. et Zucc; Daphne genkwa Sieb. et Zucc; Aloe ferox Mill; Phorboc diester; Tripterygium wilfordii Hook .f.; Lycoris radiata (L Her)Herb; Atractylodes macrocephala Koidz; Lilium brownii F.E. Brown Var; Paeonia suffruticosa Andr.; Angelica sinensis (Oliv.) Diels; Asparagus cochinensis (Lour. )Merr; Isatis tinctoria L.; Leonurus heterophyllus Sweet; Phytolacca acinosa Roxb.; Trichosanthes kirilowii Maxim; Dioscorea opposita Thumb; Schisandra chinensis (Rurcz. )Baill.; Auium Sativum L; Isatis tinctoria, L; Ligustisum Chvanxiong Hort; Glycyrrhiza uralensis Fisch; Euphorbia Kansui Liou; Polygala tenuifolia Willd; Evodia rutaecarpa (Juss.) Benth; Chelidonium majus L; Rumax madaeo Mak; Sophora Subprostmousea Chunet T.ehen; Strychnos mux-vomical; Acanthopanax senticosus (Rupr.et Maxim.)Harms; Rubia cordifolia L. Anti leukemic compounds, which were isolated from medicinal plants are ginsenoside Ro, ginsenoside Rh2, Emodin, Yuanhuacine, Aleemodin, phorbocdiester, Triptolide, Homolycorine, Atractylol, Colchicnamile, Paeonol, Aspargus polysaccharide A.B.C.D, Indirubin, Leonunrine, Acinosohic acid, Trichosanthin, Ge 132, Schizandrin, allicin, Indirubin, cmdiumlactone chuanxiongol, 18A glycyrrhetic acid, Kansuiphorin A 13 oxyingenol Kansuiphorin B. These investigation suggest that it may be very useful for developing more effective anti leukemic new dregs from medicinal plants.

• Journal of Ginseng Research
• /
• v.26 no.3
• /
• pp.111-131
• /
• 2002

Korean ginseng (Panax ginseng C.A. Meyer) received a great deal of attention from the Orient and West as a tonic agent, health food and/or alternative herbal therapeutic agent. However, controversy with respect to scientific evidence on pharmacological effects especially, evaluation of clinical efficacy and the methodological approach still remains to be solved. Author reviewed those articles published since 1980 when pharmacodynamic studies on ginseng have intensively started. Special concern was paid on metabolic disorders including diabetes mellitus, circulatory disorders, malignant tumor, sexual dysfunction, and physical and mental performance to give clear information to those who are interested in pharmacological study of ginseng and to promote its clinical use. With respect to chronic diseases such as diabetes mellitus, atherosclerosis, high blood pressure, malignant disorders, and sexual disorders, it seems that ginseng plays preventive and restorative role rather than therapeutics. Particularly, ginseng plays a significant role in ameliorating subjective symptoms and preventing quality of life from deteriorating by long term exposure of chemical therapeutic agents. Also it seems that the potency of ginseng is mild, therefore it could be more effective when used concomitantly with conventional therapy. Clinical studies on the tonic effect of ginseng on work performance demonstrated that physical and mental dysfunction induced by various stresses are improved by increasing adaptability of physical condition. However, the results obtained from clinical studies cannot be mentioned in the indication, which are variable upon the scientist who performed those studies. In this respect, standardized ginseng product and providing planning of the systematic clinical research in double-blind randomized controlled trials are needed to assess the real efficacy for proposing ginseng indication. Pharmacological mode of action of ginseng has not yet been fully elucidated. Pharmacodynamic and pharmacokinetic researches reveal that the role of ginseng not seem to be confined to a given single organ. It has been known that ginseng plays a beneficial role in such general organs as central nervous, endocrine, metabolic, immune systems, which means ginseng improves general physical and mental conditons. Such multivalent effect of ginseng can be attributed to the main active component of ginseng,ginsenosides or non-saponin compounds which are also recently suggested to be another active ingredients. As is generally the similar case with other herbal medicines, effects of ginseng cannot be attributed as a given single compound or group of components. Diversified ingredients play synergistic or antagonistic role each other and act in harmonized manner. A few cases of adverse effect in clinical uses are reported, however, it is not observed when standardized ginseng products are used and recommended dose was administered. Unfavorable interaction with other drugs has also been suggested, which the information on the products and administered dosage are not available. However, efficacy, safety, interaction or contraindication with other medicines has to be more intensively investigated in order to promote clinical application of ginseng. For example, daily recommended doses per day are not agreement as 1-2g in the West and 3-6 g in the Orient. Duration of administration also seems variable according to the purpose. Two to three months are generally recommended to feel the benefit but time- and dose-dependent effects of ginseng still need to be solved from now on. Furthermore, the effect of ginsenosides transformed by the intestinal microflora, and differential effect associated with ginsenosides content and its composition also should be clinically evaluated in the future. In conclusion, the more wide-spread use of ginseng as a herbal medicine or nutraceutical supplement warrants the more rigorous investigations to assess its effacy and safety. In addition, a careful quality control of ginseng preparations should be done to ensure an acceptable standardization of commercial products.

• The Korean Journal of Pharmacology
• /
• v.10 no.2
• /
• pp.1-11
• /
• 1974

Results of an experiment on the behavior of rats and mice in order to explore the possible pharmacological actions of Panax ginseng upon the central nervous system can be summarized as follows: 1. Spontaneous motor activity. In the case of mice, those groups who were administered 2.5 mg and 5.0mg of ginseng saponin per kilogram of body weight were observed to have increased their activity compared with the control group, while the 50.0 mg and 100.0 mg per kilogram body weight groups demonstrated lower levels of activity, with the peak of activity appearing at 30 minutes after administration of drugs. In the case of rats, those groups of animals who were given injections in the dosage of 2.5 mg, 5.0 mg and 50.0 mg per kilogram body weight demonstrated higher activity than the control group, while the 100.0 mg per kilogram group appeared to have decreased in their activity, with the peak action appearing 30 minutes after the administration of ginseng saponin. The 50.0 mg per kilogram group demonstrated no significant differential. 2. General behavior analysis. In the case of mice, decrease in sleeping component of behavior and increase in the walking and roaring components, compared those with the control group, turned out to be a common phenomenon among the groups who were administered 2.5 mg, 5.0 mg and 50.0 mg of ginseng saponin per kilogram body weight, with the 5.0 mg per kilogram group standing out of all the other groups in terms of their reactions. In the case of rats, ginseng saponin appeared to reduce sleeping component with 2.5 mg, 5.0 mg and 50.0 mg per kilogram body weight groups, while increased the walking and rearing components. It was observed that administratoin of ginseng saponin in a dose of 2.5 mg per kilogram appeared to markedly increase the lying and grooming components of animal behavior. 3. Open-field exploratory behavior. Adminstration of ginseng saponin to mice in doses of 5.0 mg, 50.0 mg and 100.0 mg per kilogram body weight decreased activity, but increased their exploratory behavior. In the case of rats, however, administration of ginseng saponin in the doses of 2.5 mg and 5.0 mg per kilogram body weight markedly increased their activities, while decreased activities with the 50.0 mg per kilogram and 100.0 mg per kilogram groups. The exploratory behavior of rats appeared to have decreased, while grooming increased ramarkably. 4. The above findings from a series of experiment appear to suggest a stimulating effect on the central nervous system when ginseng saponin is administered in small doses, but that larger doses might result in an inhibitory effect, though differential results can be anticipated with modification of experimental conditions.

• Journal of Microbiology and Biotechnology
• /
• v.18 no.2
• /
• pp.263-269
• /
• 2008

Hydrazinocurcumin (HC), a synthetic derivative of curcumin, has been reported to inhibit angiogenesis via unknown mechanisms. Understanding the molecular mechanisms of the drug's action is important for the development of improved compounds with better pharmacological properties. A genome-wide drug-induced haploinsufficiency screening of fission yeast gene deletion mutants has been applied to identify drug targets of HC. As a first step, the 50% inhibition concentration $(IC_{50})$ of HC was determined to be $2.2{\mu}M$. The initial screening of 4,158 mutants in 384-well plates using robotics was performed at concentrations of 2, 3, and $4{\mu}M$. A second screening was performed to detect sensitivity to HC on the plates. The first screening revealed 178 candidates, and the second screening resulted in 13 candidates, following the elimination of 165 false positives. Final filtering of the condition-dependent haploinsufficient genes gave eight target genes. Analysis of the specific targets of HC has shown that they are related to septum formation and the general transcription processes, which may be related to histone acetyltransferase. The target mutants showed 65% growth inhibition in response to HC compared with wild-type controls, as shown by liquid culture assay.

• The Korean Journal of Pharmacology
• /
• v.8 no.1
• /
• pp.49-57
• /
• 1972

Ginseng, the Korean medicinal radix, has been widely used in the Chinese medicine as well as in the folk remedies for many centuries. It is claimed from experience that ginseng exerts multiple therapeutic effects in a large variety of disorders. Despite of its popularity, the chemical analysis and pharmacological study of ginseng are not firmly established. Although there are some scattered reports of ginseng effects on blood pressure, there are few reports on hypertension especially. Recently, Lee & Cho (1971) reported that the administration of ginseng significantly supresses the production of renal hypertension. This study was undertaken to reevaluate the effect of ginseng on renal hypertension and to determine whether ginseng also supresses on neurogenic hypertension, and to clarify the mechanism of this antihypertensive effect. Male rats, weighing around 180 gm on an average were used. Renal hypertension was induced by Grollman's method under general anesthesia with 35mg/kg of pentobarbital sodium. Ginseng effect on blood pressure was observed on normal, renal hypertensive and neurogenic hypertensive rats respectively. Ginseng alcohol extract (40mg/kg) was administered daily subcutaneously from 3 days prior to producing hypertension. And in renal hypertensive rats, the effects of histamine and Avil on blood pressure were also observed. Histamine (0.05mg/kg) and Avil (0.025mg/kg) were also administered daily I.M. from 3 days prior to kidney-8-ligature. The results of the experiments are as follows: 1) No significant difference was observed in blood pressure between the normotensive control and ginseng-treated normotensive rats. 2) In renal hypertensive control, the mean blood pressure already was significantly elevated on 15th day and gradually elevated. The administration of ginseng significantly supresses the production of renal hypertension from 30th day as compared with control rats. 3) The mean blood pressure in neurogenic hypertensive control was average 143.1 mmHg on 7th day. On the other hand, in ginseng treated-neurogenic hypertensive rats, the mean blood pressure was average 125.5mmHg. The administration of ginseng significantly supresses the production of neurogenic hypertension as compared with control rats. 4) In renal hypertensive rats, the administration of histamine and Avil did not differ with control rats. 5) In ginseng-treated renal hypertensive rats, cholesterol contents of plasma, adrenal, kidney and spleen were slightly decreased.

• The Korean Journal of Pharmacology
• /
• v.32 no.1
• /
• pp.39-49
• /
• 1996

In the present study, we observed change in intracellular $Ca^{2+}$$([Ca^{2+}]_i)$ as measured with the fluorescent $Ca^{2+}-indicator$ fura-2 in association with force development of the rat basilar arteries during activation by$K^+$ depolarizing solution and U46619, a thromboxane analogue, in the absence and the presence of calcitonin-gent related peptide (CGRP). CGRP (30 and 100 nM) caused a concentration-dependent inhibition of U46619-induced contraction with decrease in $[Ca^{2+}]_i$, whereas it did not exert any effect on the $K^+$ (90 mM)-induced contraction and increase in $[Ca^{2+}]_i$, Further, $[Ca^{2+}]_i-force$ relationships were determined by plotting the ratio of $F_{340}/F_{380}$ $([Ca^{2+}]_i)$ as a function of the force induced by U46619, and the results were compared with those obtained in the presence of CGRP. The curves obtained in the presence of CGRP (30 and 100 nM) were significantly moved to downward without right shift of the curves suggesting that CGRP inhibited the U46619-induced contraction only by mediation of reduction in $[Ca^{2+}]_i$ with out any change in the sensitivity of contractile apparatus to $Ca^{2+}$. The CGRP-induced attenuation of $[Ca^{2+}]_i$ and force development was significantly inhibited under pretreatment with CGRP $(8{\sim}37)$ fragment (100 nM), a CGRP1 receptor antagonist. Both the reduced contraction and reduction in $[Ca^{2+}]_i$ caused by CGRP were fully reversed by pretreatment with charybdotoxin (100 nM) and iberiotoxin (100 nM), large conductance $Ca^{2+}-activated$ $K^+$ channel blockers, but not by apamin (300 nM), a small conductance $Ca^{2+}-activated$ $K^+$ channel blocker, and glibenclamide ( 1 ${\mu}M$), an ATP-sensitive $K^+$ channel blocker. In conclusion, it is suggested that the CGRP1 receptor, upon activation by CGRP, are coupled to opening of $Ca^{2+}-activated$ $K^+$ channel and cause to decrease in $[Ca^{2+}]_i$, thereby leading to vasodilation of the rat basilar artery. However, it is not defined that the mechanism underlying vasodilation whether the $K^+$ channel blockers, charybdotoxin and iberiotoxin directly block the CGRP receptors and that CGRP-evoked relaxation is dependent on the cyclic AMP or $K^+$ channel opening or both actions.